The opioid system is a critical component of the human body’s neurochemical network, playing a central role in regulating pain, reward, and emotional responses. It consists of opioid receptors—primarily mu, delta, and kappa—found throughout the brain, spinal cord, and other tissues, along with endogenous opioid peptides such as endorphins, enkephalins, and dynorphins. These naturally occurring substances bind to receptors to modulate sensations of pain and stress, as well as to influence mood and behaviour. Understanding the opioid system is essential not only for appreciating how the body maintains balance in response to physical and emotional stimuli but also for addressing the challenges associated with opioid-based medications and addiction.

Delta-type Opioid Receptor (DOR)

The delta-type opioid receptor (DOR) is one of the three main classes of opioid receptors in the body, alongside mu and kappa receptors. While it shares structural similarities with the others, the DOR has distinct functions, particularly in modulating mood, emotional responses, and certain types of pain. Found primarily in areas of the brain involved in emotion and cognition, the DOR is activated by the body’s own peptides, such as enkephalins.

Compounds that bind to the delta opioid receptor can produce a range of effects. These may include analgesia (pain relief), as well as mood-enhancing or antidepressant-like effects, making DOR a potential target for treating chronic pain and mood disorders. However, overstimulation or long-term activation of this receptor may also be associated with pro-convulsant activity or tolerance development, highlighting the need for careful drug design and therapeutic targeting.

Kappa-type Opioid Receptor (KOR)

The kappa-type opioid receptor (KOR) is widely distributed in the brain, spinal cord, and peripheral nervous system, and is primarily activated by endogenous peptides known as dynorphins. KOR plays a complex role in regulating pain perception, stress responses, mood, and consciousness.

Compounds that bind to the kappa opioid receptor can produce potent analgesic (pain-relieving) effects, particularly in the spinal cord. However, unlike drugs targeting the mu receptor, KOR agonists generally have a lower risk of respiratory depression or addiction. On the downside, activation of KOR is often associated with unpleasant side effects such as dysphoria (a state of emotional discomfort), anxiety, or hallucinations. These effects have limited the clinical use of KOR agonists, but the receptor remains an active area of research for novel treatments for pain, addiction, and mood disorders.

Mu-type Opioid Receptor (MOR)

The mu-type opioid receptor (MOR) is the most well-known of the opioid receptors and is the primary target of many commonly used opioid drugs, including morphine, fentanyl, and oxycodone. This receptor is found throughout the brain and spinal cord, especially in areas involved in pain processing and reward.

When a compound binds to the mu opioid receptor, it typically produces strong analgesic (pain-relieving) effects. In addition to pain relief, activation of MOR can cause feelings of euphoria, which contributes to its role in reward and addiction. Other effects may include sedation, a slowing of breathing (respiratory depression), constipation, and in high doses or with prolonged use, tolerance and physical dependence.

Because of these powerful and wide-ranging effects, the mu receptor is central to both the medical use of opioids and the challenges associated with their misuse and addiction.